FMC Submits First Global Regulatory Filing for Dual-Action Herbicide Rimisoxafen
Event summary
- FMC Corporation submitted the first global regulatory dossier for rimisoxafen to the U.S. EPA on July 8, 2026.
- Rimisoxafen is classified as a dual mode of action herbicide by HRAC, targeting two distinct biochemical pathways in weeds.
- The submission covers use on corn, soybean, sunflower, and select pulse crops in the U.S.
- FMC has conducted over 1,000 field and greenhouse studies supporting rimisoxafen's development.
The big picture
FMC's submission of rimisoxafen comes as herbicide-resistant weeds pose growing challenges for U.S. growers, with the market spending over $6 billion annually on weed control. The dual mode of action technology represents a strategic response to intensifying resistance pressures in key row crop markets. This filing is part of FMC's broader effort to strengthen its R&D pipeline and maintain leadership in next-generation crop protection solutions.
What we're watching
- Regulatory Approval Timeline
- The pace at which the EPA and other global regulators review and approve rimisoxafen will determine its commercialization timeline.
- Market Adoption
- Whether growers will embrace rimisoxafen as a solution to herbicide-resistant weeds, particularly Palmer amaranth and waterhemp.
- Pipeline Productivity
- How FMC's ability to advance multiple novel herbicides through regulatory processes impacts its long-term competitive position.